First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. - Wikidata - awgldk - TriplyDB

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.

http://www.wikidata.org/entity/Q34917310

about

Guanylate cyclase stimulators for pulmonary hypertension Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat Medical treatment update on pulmonary arterial hypertension Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Recent trends in pulmonary arterial hypertension Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.New approaches to the treatment of pulmonary hypertension: from bench to bedside.Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Treating pulmonary arterial hypertension: current treatments and future prospects The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Update on pulmonary hypertension 2009.Advances in pediatric pulmonary arterial hypertension.A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension.Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension.Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.Emerging drugs for pulmonary hypertension.Riociguat for pulmonary hypertension.New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.Pulmonary hypertension: advances in pathogenesis and treatment.Right ventricular failure: a novel era of targeted therapy.Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.Riociguat for the treatment of pulmonary hypertension.

P2860

Q26470534-B92C3F43-D45C-4058-A114-A8C314661635 Q26746202-CEF69C67-821B-4C34-AE94-AE33E912C87B Q26785995-C91C95B1-E145-47D9-AF10-8C57B5211C5A Q27023074-1D723BBE-08DC-4363-A7F4-F071568AE073 Q28742463-7B4DFCC3-EE4F-4CEB-BB5F-D265B7ECBA25 Q30475192-C309D4C4-84A6-4CEC-9B4B-59250C40F226 Q33447738-A91296CA-0BEB-455A-93B1-554D5F9DECD7 Q33596457-E097D8CE-9E12-4656-A92F-994B628256BD Q33690368-EA7A19A1-413F-4359-B16C-8A0D28B82C61 Q33810499-BDAD3541-3E9F-497A-9ADE-BB47A115197B Q33965904-3ED9F833-9299-4E25-8204-80FA59DBA983 Q34122462-51FF22DE-5767-478D-B198-1B8831F96D98 Q34179857-4302EB78-0348-4825-8CAF-308FBDF143C4 Q34318473-30962C3E-20BF-4D8D-AD75-5FD8E63FAD82 Q34389618-DBCE6EB7-409A-412A-83F6-BBF4DD53C2ED Q34444990-B8AC06ED-5B7F-4734-8C5F-080F4D2D8C06 Q34448355-E6BFB00E-A0D9-4455-B46C-0C2070EB064B Q34778575-65B9DA4C-E95E-46D1-B9C9-8A530EC309CC Q34981737-16C1B966-CF1E-483D-8A55-C1881FA6BC86 Q35010064-6E9B9158-2F4A-4EA6-8BB1-385F461B4A94 Q35075847-0BF64E32-18E4-439D-8553-1F023BAC7AE3 Q35665739-CFA125D2-7631-405F-A54A-ADBD41CB312B Q35716098-AC7E7719-FE12-47EA-B314-6F2E8C9F67B2 Q35869437-34DD2DAB-D579-4F00-BADC-BC7C23FA0AEC Q36481525-266F15C3-87EC-4C51-A4C5-9D6AD451D4F3 Q36734217-2B4A13E9-E7F8-4F7D-B1DE-A384254FA796 Q36795578-699CF007-9E2B-4A84-888E-1F24D663207B Q36881704-8D63FDE5-8837-4031-A012-01E8A59B2849 Q36881715-6E72D481-A1E5-49D1-B567-C50760183BF1 Q36881722-F28A9257-12A7-44E0-93A2-CDB88DEA5C5B Q36881733-4598DD17-3D77-4287-A2D8-27A03EAFEF4B Q37464964-0BB3152B-D691-4B85-B181-45A6F95150A2 Q37486257-3FFC9A97-5A88-4E81-9B95-EC555D033AEB Q37679940-E968241B-8AC6-42EB-8FD0-E5AFBB5A34EB Q37709398-09567DD7-1806-4030-8630-EA578CE09016 Q37724192-4D9BCBC0-FD5F-4DA7-9623-BDA3E44EB3E2 Q37744182-A3310D83-3235-4E51-84D8-06BB13A66518 Q37796685-B87063D2-18AE-4234-8FD6-3E3A565D32B7 Q37823027-8A4EA110-EF0A-4C21-81DC-C42A48453EF3 Q37851516-30DDD064-D637-4166-AAE2-070ADCEAE215

P2860

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.

http://www.wikidata.org/entity/Q34917310

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

First acute haemodynamic study ...... uat in pulmonary hypertension.

@ast

First acute haemodynamic study ...... uat in pulmonary hypertension.

@en

First acute haemodynamic study ...... uat in pulmonary hypertension.

@nl

type

label

First acute haemodynamic study ...... uat in pulmonary hypertension.

@ast

First acute haemodynamic study ...... uat in pulmonary hypertension.

@en

First acute haemodynamic study ...... uat in pulmonary hypertension.

@nl

prefLabel

First acute haemodynamic study ...... uat in pulmonary hypertension.

@ast

First acute haemodynamic study ...... uat in pulmonary hypertension.

@en

First acute haemodynamic study ...... uat in pulmonary hypertension.

@nl

P1433

Q34917310-54F3143B-AC1A-471F-93A7-B73DA4DA5E11

P1476

Q34917310-EF9311E5-BF0E-48A5-8D9E-BAE5830B9B7E

P2093

Q34917310-0A09B596-91A0-448E-9BB4-5D276FD00D81

Q34917310-4D1C62D5-017F-44DC-B209-6FD892A0421B

Q34917310-5D32F25A-F6E4-44B8-8059-2ACF69A0566B

Q34917310-6552F4D4-ADC1-4AFF-9FAD-BB48E9202396

Q34917310-6C9D2EE4-F448-4014-8DD1-27C960E5FBB8

Q34917310-7677665D-2319-4FC4-804B-CAA89323D9FC

Q34917310-A8A79453-3510-442C-ABEC-01104AB53C6A

Q34917310-BCA43085-D7CA-41DC-A9B4-DD799F6043AA

Q34917310-C15DA698-B4B7-4A2C-A735-D73CB361F524

Q34917310-DA204892-9A5A-4A94-B2A5-6ECC61A98626

P304

Q34917310-ADA06876-3BCF-4C85-BDCB-8E398AE575D1

P31

Q34917310-39ECFC44-BE8F-4A83-9EFA-7AB7B05030FE

P356

Q34917310-296FC168-C998-41D1-9274-803F849A3B0B

P433

Q34917310-CCB801F7-7318-4191-BB11-6E7DB5F924CE

P478

Q34917310-F01B5B95-2710-4DBD-9148-51659E336F92

P50

Q34917310-4077BAA0-101C-41CB-8AAB-AA27CB6A29DC

Q34917310-CC1A0036-B97A-4FD5-A0DF-BA4CB4EF25FF

P577

Q34917310-A3E7C62B-B743-4DD2-8757-EB9F54D928CA

P5875

Q34917310-DCE423C8-D8FA-45FD-B671-3D1803FBA1AF

P698

Q34917310-61AB8D6C-6612-418E-8E24-86AE08AFC16A

P921

Q34917310-018B2BCA-92D8-4034-BF71-811BCF4B2E5F

Q34917310-8DB8A096-57B7-4F2A-8B6F-AFBAB4D922B9

P356

09031936.00039808

P1433

European Respiratory Journal

P1476

First acute haemodynamic study ...... uat in pulmonary hypertension.

@en

P2093

D Bölkow

http://www.w3.org/2001/XMLSchema#string

G Weimann

http://www.w3.org/2001/XMLSchema#string

G Wensing

http://www.w3.org/2001/XMLSchema#string

H A Ghofrani

http://www.w3.org/2001/XMLSchema#string

M Thamm

http://www.w3.org/2001/XMLSchema#string

R Frey

http://www.w3.org/2001/XMLSchema#string

R T Schermuly

http://www.w3.org/2001/XMLSchema#string

R Voswinckel

http://www.w3.org/2001/XMLSchema#string

S Unger

http://www.w3.org/2001/XMLSchema#string

W Mück

http://www.w3.org/2001/XMLSchema#string

P304

785-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.00039808

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Friedrich Grimminger

Norbert Weissmann

P577

2009-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50909386

http://www.w3.org/2001/XMLSchema#string

P698

19129292

http://www.w3.org/2001/XMLSchema#string

P921